[Metabolic effects of angiotensin-II receptor blockers].
Oganov
R G
RG
Nebieridze
D V
DV
D000179:Acrylates / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000378:metabolism*; D005337:Fibrin / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male; D011945:Receptors, Angiotensin / Q000378:metabolism*; D013876:Thiophenes
D000179:Acrylates; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007093:Imidazoles; D011945:Receptors, Angiotensin; D013876:Thiophenes; D000804:Angiotensin II; C068373:eprosartan; D005337:Fibrin; D002784:Cholesterol